Aspen Aerogels IncASPN

Two customers still drove 42% of Aspen Aerogels Inc’s revenue in the first quarter of 2026, down from 74% in the same period last year, a concentration that would make any finance chief reach for the antacids rather than the champagne. The company’s 10-Q filed on 8 May 2026 shows revenue of $37.9 million for the three months to 31 March 2026, yet the net loss widened to $23.7 million and the operating loss ballooned to $20.8 million, revealing that the firm’s vaunted aerogel platform has yet to translate into bottom-line cheer.

Founded in 2001, Aspen makes ultralight aerogel materials marketed for energy-industrial insulation, sustainable building wraps, and electric-vehicle battery barriers. Its PyroThin product line is a paper-thin fire shield designed to slow thermal runaway at cell-to-cell, module, and pack levels, while Cryogel Z targets cryogenic pipelines and LNG tanks. The company also sells technical-services engineering to solve “some of thermal insulation’s toughest challenges,” a line that sounds grand until you notice the operating loss is doing push-ups in the red-ink gym.

For the quarter ending 31 March 2026 Aspen posted revenue of $37.9 million, a net loss of $23.7 million, an operating loss of $20.8 million, and an EPS loss of 29 cents on 82.7 million diluted shares. Cash and equivalents stood at $173.9 million, up $34.1 million in operating cash during the quarter despite the red ink; inventories fell by $7.2 million; and the balance sheet carried $410.5 million of assets against $197.0 million of liabilities. R&D was a modest $2.7 million while capital expenditure was only $1.4 million-numbers that do not scream “scale factory” so much as “small shop with big dreams.”

The company’s public story is built on images of engineers holding PyroThin samples and on a technology-platform wall of patents, yet the 10-Q’s line items tell a different tale. The 2026-05-18 8-K highlights the “strategic importance” of the OPE automated PyroThin facility in Mexico, but the quarterly filing does not quantify its revenue contribution or margin impact. The same document dumps a raft of insider-transaction disclosures without clarifying how any of them move the needle on profitability. Meanwhile, Aspen’s technical-services page invites customers to “contact us today for support your next project,” language that sounds more desperate than differentiated when the operating loss is still six figures per quarter.

For a deeper look at the filing trail, readers can scan the SEC’s EDGAR index for Aspen Aerogels Inc (CIK 1145986) or pull the raw JSON submissions feed, but the takeaway remains the same: the platform narrative is glossy while the ledger is bruised. The company’s cash is real, its product pipeline is documented, and its customer concentration is slowly diversifying, yet none of those facts change the core arithmetic that a $37.9 million revenue engine is burning through tens of millions of losses every quarter. Until the operating loss narrows materially, the gap between the PyroThin brochure and the 10-Q will keep widening.

What changed this week: the 10-Q filing on 8 May 2026 updated revenue, loss, cash, inventory, and EPS for the quarter ending 31 March 2026; the 2026-05-18 8-K reiterated the “strategic importance” of the OPE automated facility without adding financial metrics; and the 2026-06-26 4 filing added insider-transaction disclosures. No new product launches, no contract wins, and no regulatory approvals were cited in the supplied evidence.

What remains unproven: Aspen has not demonstrated that its aerogel portfolio can scale profitability at current revenue levels; the OPE facility’s financial contribution is undisclosed; and the diversification away from customer concentration has not yet translated into margin improvement. Evidence that would deepen the file next would include a quarter with positive operating income, segment-level margins for PyroThin and Cryogel Z, and quantitative disclosures on OPE’s revenue and EBITDA contribution.